This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mgbonyebi, O. P. Articles by Russo, I. H. Search for Related Content PubMed PubMed Citation Articles by Mgbonyebi, O. P. Articles by Russo, I. H.

Roscovitine Induces Cell Death and Morphological Changes Indicative of Apoptosis in MDA-MB-231 Breast Cancer Cells¹

Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

We have previously shown (Mgbonyebi et al., Anticancer Res., 18: 751–756, 1998) that roscovitine, an olomoucine-related purine analogue and a selective inhibitor of cyclin-dependent kinases, inhibited the proliferative activity of human breast epithelial cells in vitro. The purpose of the present study was to identify the cellular processes and targets affected by roscovitine treatment in the estrogen receptor-negative MDA-MB-231 human breast carcinoma cells. Treatment of the cells with 10 µg/ml roscovitine daily for a length of time ranging from 24 to 240 h revealed that the compound inhibited DNA synthesis, induced cell death, and irreversibly inhibited the proliferative activity of the cells. Morphological analysis of roscovitine-treated cells by light and fluorescence microscopy demonstrated that this cyclin-dependent kinase inhibitor induced cell shrinkage, chromatin condensation, reorganization of actin microfilament architecture, and extensive detachment of cells from the cell culture substratum. These cellular events are all known to be associated with apoptosis. Collectively, the data generated from this study suggest that roscovitine induced apoptosis in the estrogen receptor-negative MDA-MB-231 human breast cancer cells. Because the efficacy of many anticancer drugs depends on their ability to induce apoptotic cell death, modulation of this parameter by roscovitine may provide a new chemopreventive and chemotherapeutic strategy for the clinical management of hormone-resistant breast cancers.

This article has been cited by other articles:

				M. Mody, N. Dharker, M. Bloomston, P.-S. Wang, F.-S. Chou, T. S Glickman, T. McCaffrey, Z. Yang, A. Pumfery, D. Lee, et al. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-{alpha}, CH11 and CYC202 Endocr. Relat. Cancer, June 1, 2007; 14(2): 305 - 315. [Abstract] [Full Text] [PDF]

				E. Crescenzi, G. Palumbo, and H. J.M. Brady Roscovitine Modulates DNA Repair and Senescence: Implications for Combination Chemotherapy Clin. Cancer Res., November 15, 2005; 11(22): 8158 - 8171. [Abstract] [Full Text] [PDF]

				O. M. Tirado, S. Mateo-Lozano, and V. Notario Roscovitine Is an Effective Inducer of Apoptosis of Ewing's Sarcoma Family Tumor Cells In vitro and In vivo Cancer Res., October 15, 2005; 65(20): 9320 - 9327. [Abstract] [Full Text] [PDF]

				S. L. Maude and G. H. Enders Cdk Inhibition in Human Cells Compromises Chk1 Function and Activates a DNA Damage Response Cancer Res., February 1, 2005; 65(3): 780 - 786. [Abstract] [Full Text] [PDF]

				P. M. Price, R. L. Safirstein, and J. Megyesi Protection of renal cells from cisplatin toxicity by cell cycle inhibitors Am J Physiol Renal Physiol, February 1, 2004; 286(2): F378 - F384. [Abstract] [Full Text] [PDF]

				S. Mohapatra, B. Chu, S. Wei, J. Djeu, P. K. Epling-Burnette, T. Loughran, R. Jove, and W. J. Pledger Roscovitine Inhibits STAT5 Activity and Induces Apoptosis in the Human Leukemia Virus Type 1-Transformed Cell Line MT-2 Cancer Res., December 1, 2003; 63(23): 8523 - 8530. [Abstract] [Full Text] [PDF]

				L. Maggiorella, E. Deutsch, V. Frascogna, N. Chavaudra, L. Jeanson, F. Milliat, F. Eschwege, and J. Bourhis Enhancement of Radiation Response by Roscovitine in Human Breast Carcinoma in Vitro and in Vivo Cancer Res., May 15, 2003; 63(10): 2513 - 2517. [Abstract] [Full Text] [PDF]

				C. Yu, M. Rahmani, Y. Dai, D. Conrad, G. Krystal, P. Dent, and S. Grant The Lethal Effects of Pharmacological Cyclin-dependent Kinase Inhibitors in Human Leukemia Cells Proceed through a Phosphatidylinositol 3-Kinase/Akt-dependent Process Cancer Res., April 15, 2003; 63(8): 1822 - 1833. [Abstract] [Full Text] [PDF]

				D. L. Evers, J. M. Breitenbach, K. Z. Borysko, L. B. Townsend, and J. C. Drach Inhibition of Cyclin-Dependent Kinase 1 by Purines and Pyrrolo[2,3-d]Pyrimidines Does Not Correlate with Antiviral Activity Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2470 - 2476. [Abstract] [Full Text] [PDF]

				M. Ljungman and M. T. Paulsen The Cyclin-Dependent Kinase Inhibitor Roscovitine Inhibits RNA Synthesis and Triggers Nuclear Accumulation of p53 That Is Unmodified at Ser15 and Lys382 Mol. Pharmacol., October 1, 2001; 60(4): 785 - 789. [Abstract] [Full Text] [PDF]